David Mitchell: Advocate for Affordable Prescription Drugs

David Mitchell, a public relations executive and cancer patient, became a prominent advocate for lowering prescription drug prices after his own diagnosis in 2010. He passed away on January 2, 2026, at the age of 75 due to multiple myeloma, a type of blood cancer he had battled for 15 years.

New York Times

Mitchell's journey into advocacy began when he was diagnosed with cancer, prompting him to postpone retirement and focus on the escalating costs of his medications. By 2016, his annual medication expenses reached $300,000, a burden he managed through insurance but recognized was unmanageable for many others. This realization fueled his frustration and anger towards the pharmaceutical industry.

New York Times

As a founding partner of GMMB, a Washington-based communications firm, Mitchell utilized his expertise in public relations to address the issue of high drug prices. He became a leading voice in campaigns aimed at reforming prescription drug pricing, drawing on his extensive experience in public health advocacy.

New York Times

Mitchell's advocacy highlighted the broader implications of high prescription drug costs on public health and access to necessary medications. His statements and campaigns aimed to raise awareness of the financial burdens faced by patients, contributing to ongoing discussions about healthcare reform in the United States.

New York Times

In a statement following his death, Mitchell's family emphasized his commitment to advocating for those unable to afford their medications. His perspective on the pharmaceutical industry was stark; he likened the pricing strategies to extortion, stating, “It’s like extortion... It’s no different than Tony Soprano walking into a store and saying, ‘Someone may get hurt if you don’t give us the money.’”

New York Times

While Mitchell's advocacy garnered significant support, it also faced criticism from pharmaceutical companies and some policymakers who argue that high drug prices are necessary to fund research and development. This ongoing debate reflects the complexities of healthcare economics and the challenges in balancing innovation with affordability.

New York Times

• “It’s like extortion,” — David Mitchell, Advocate for Lower Prescription Drug Prices

New York Times

• “It’s no different than Tony Soprano walking into a store and saying, ‘Someone may get hurt if you don’t give us the money.’” — David Mitchell, on pharmaceutical pricing strategies

New York Times

David Mitchell's legacy as an advocate for affordable prescription drugs underscores the urgent need for reform in the healthcare system, particularly as the costs of medications continue to rise. His efforts have sparked important conversations about access to healthcare and the ethical responsibilities of the pharmaceutical industry.

New York Times